Loading...
Loading...
Almirall and Forest Laboratories
FRX today
announced positive topline results from a six month pivotal phase III
clinical trial evaluating the efficacy and safety of fixed dose
combinations of aclidinium bromide, (LAMA) and formoterol fumarate
(LABA) delivered by Almirall's inhaler Genuair® (Pressair™ in
the USA).
Both combinations of aclidinium/formoterol (400/6mcg and 400/12mcg given
twice a day) demonstrated statistically significant improvements in the
co-primary endpoints of change from baseline in morning predose trough
FEV1 versus formoterol 12mcg and in FEV1 at 1 hour post-dose versus
aclidinium 400mcg at week 24 (p<0.01 and p≤0.0001, respectively). In
addition, both combinations of aclidinium/formoterol (400/6mcg and
400/12mcg) provided
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in